BioLife Solutions, Inc.
Bear Case (25th pct.)
-103.4% vs price
Base Case (Median)
-80.1% vs price
Bull Case (75th pct.)
-55.7% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-7.07 | -119.9% | High (40%) |
| PE Comparable | $22.70 | -36.0% | Medium (25%) |
| Graham Number | $13.37 | -62.3% | Medium (40%) |
| EV/EBITDA | $0.76 | -97.9% | Medium (20%) |
Based on 4 out of 8 methods, BLFS appears overvalued at the current price of $35.45. The base case fair value of $7.06 implies 80.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.